Physician profile
Daniel Gaitan
NPI 1598865636
$34,097.54
in general payments reported to CMS, 2019-2025
44 companies · $2,170 in 2025
The $2,170 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $1,128 · 2021: $244 · 2022: $236 · 2023: $337 · 2024: $82.51 · 2025: $2,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,130 · Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,130.00 |
| Food and Beverage | $459.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $26,540.70 | 2019 | |
| Novo Nordisk INC | $2,734.88 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $684.90 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $633.70 | 2019-2020 | |
| Abbvie INC. | $571.27 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $256.17 | 2019-2020 | |
| Abbott Laboratories | $237.11 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $198.41 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.51 | 2019-2020 | |
| Horizon Therapeutics Plc | $192.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $168.81 | 2019-2024 | |
| Lilly USA, LLC | $159.89 | 2019-2021 | |
| Amarin Pharma, INC. | $149.22 | 2019-2020 | |
| Ucb, INC. | $125.00 | 2019 | |
| Bausch Health US, LLC | $113.29 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gaitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.